DelveInsight’s, “CRISPR Therapies Pipeline Insight, 2025,” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the CRISPR Treatment Landscape. Click here to read more @ CRISPR Pipeline Outlook

Key Takeaways from the CRISPR Pipeline Report

• In June 2025, Regeneron Pharmaceuticals announced a study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the “study drug”. Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy.
• In June 2025, CRISPR Therapeutics conducted a study may enroll up to 290 subjects in total. CTX131 is a CD70-directed chimeric antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of relapsed/refractory hematological malignancies. The cells are from healthy adult volunteer donors that are genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9) gene editing components (single guide RNA and Cas9 nuclease).
• DelveInsight’s CRISPR pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for CRISPR treatment.
• The leading CRISPR Companies such as Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others.
• Promising CRISPR Pipeline Therapies such as BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others.

Stay informed about the cutting-edge advancements in CRISPR treatments. Download for updates and be a part of the revolution in cancer care @ CRISPR Clinical Trials Assessment

CRISPR Emerging Drugs Profile

• LBP-EC01: Locus Biosciences

LBP-EC01 is a Locus crPhage® therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen Escherichia coli (E. coli). It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting the E. coli genome. The precision medicine product works through a unique dual mechanism of action utilizing both the natural lytic activity of the bacteriophage and the DNA-targeting activity of CRISPR-Cas3. Laboratory tests and small animal models of urinary tract infection have demonstrated LBP-EC01 is significantly more effective at killing E. coli than corresponding natural bacteriophages, and LBP-EC01 met all primary and secondary endpoints and demonstrated safety and tolerability in a Phase 1b trial. LBP-EC01 is currently being evaluated in a registrational Phase II/III trial for the treatment of UTIs caused by E. coli.

• NTLA-2002: Intellia Therapeutics, Inc

NTLA-2002 is a wholly owned first single-dose investigational CRISPR therapeutic candidate designed to inactivate the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein. NTLA-2002 is Intellia’s second investigational CRISPR therapeutic candidate to be administered systemically, by intravenous infusion, to edit disease-causing genes inside the human body with a single dose of treatment. Intellia’s proprietary non-viral platform deploys lipid nanoparticles to deliver to the liver a two-part genome editing system: guide RNA specific to the disease-causing gene and messenger RNA that encodes the Cas9 enzyme, which together carry out the precision editing. Currently, the drug is in the Phase I/II stage of its development for the treatment of CRISPR Therapies

• CB-010: Caribou Biosciences, Inc

CB-010 is the lead clinical-stage product candidate from Caribou’s allogeneic CAR-T cell therapy platform, and it is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase I clinical trial and will be evaluated in patients with lupus nephritis (LN) and extrarenal lupus (ERL) in the GALLOP Phase 1 clinical trial. In ANTLER, Caribou is enrolling second-line patients with large B cell lymphoma (LBCL) comprised of different subtypes of aggressive r/r B-NHL (DLBCL NOS, PMBCL, HGBL, tFL, and tMZL). To Caribou’s knowledge, CB-010 is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to improve activity against diseases by limiting premature CAR-T cell exhaustion. CB-010 is also, to Caribou’s knowledge, the first anti-CD19 allogeneic CAR-T cell therapy to be evaluated in the second-line LBCL setting and, for r/r B-NHL, CB-010 has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations by the FDA. Currently, the drug is in the Phase I stage of its development for the treatment of CRISPR Therapies

The CRISPR Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of CRISPR with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CRISPR Treatment.
• CRISPR Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• CRISPR Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different CRISPR mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CRISPR market

Learn more about CRISPR Drugs opportunities in our groundbreaking CRISPR research and development projects @ CRISPR Unmet Needs

CRISPR Companies

Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others.

CRISPR Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

CRISPR Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in CRISPR Treatment by visiting our website. Stay informed about how we’re transforming the future of Hematological Disorders @ CRISPR Market Drivers and Barriers, and Future Perspectives

Scope of the CRISPR Pipeline Report

• Coverage- Global
• CRISPR Companies- Beam Therapeutics, Tango Therapeutics, CRISPR therapeutics, Caribou Biosciences, Inc., KSQ Therapeutics, Intellia Therapeutics, Inc., Locus Biosciences, CRISPR Therapeutic, and others.
• CRISPR Pipeline Therapies- BEAM-301, TNG260, CTX 130, CB-010, KSQ-4279, NTLA-2002, LBP-EC01, CTX001, and others.
• CRISPR Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• CRISPR Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of CRISPR Pipeline on our website @ CRISPR Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. CRISPR Therapies: Overview
4. Therapeutic Assessment
5. CRISPR Therapies– DelveInsight’s Analytical Perspective
6. Late Stage Products (Phase III)
7. Drug Name: Company Name
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II/III)
10. LBP-EC01: Locus Biosciences
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. NTLA-2002: Intellia Therapeutics, Inc
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. CRISPR Therapies Key Companies
20. CRISPR Therapies Key Products
21. CRISPR Therapies- Unmet Needs
22. CRISPR Therapies- Market Drivers and Barriers
23. CRISPR Therapies- Future Perspectives and Conclusion
24. CRISPR Therapies Analyst Views
25. CRISPR Therapies Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: delveinsight.com/report-store/crispr-therapies-pipeline-insight